Factors associated with lung improvement in patients treated with rituximab
| Univariate model | Multivariate model | |||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Sex | 0.84 (0.34 to 2.06) | 0.71 | ||
| Age >55 years | 0.9 (0.42 to 1.9) | 0.78 | ||
| ANA | 1.07 (0.07 to 16.77) | 0.96 | ||
| Anti-Scl70 | 0.84 (0.41 to 1.72) | 0.63 | ||
| ACA | 0.68 (0.18 to 2.64) | 0.58 | ||
| RNA pol III antibodies | 4 (0.45 to 35.38) | 0.22 | ||
| Diffuse cutaneous form | 1.57 (0.78 to 3.18) | 0.21 | ||
| Disease duration <5 years | 2.02 (0.98 to 4.17) | 0.058 | 1.94 (0.94 to 4.03) | 0.077 |
| Previous IS or biologics | 0.95 (0.47 to 1.93) | 0.89 | ||
| DLCO <70% | 1.68 (0.68 to 4.2) | 0.27 | ||
| FVC <80% | 2.05 (0.96 to 4.38) | 0.066 | 1.96 (0.91 to 4.23) | 0.089 |
Variables identified in univariate analysis with p<0.1 were tested in multivariate analysis adjusted on region. Lung fibrosis improvement was defined by increase in forced vital capacity during the follow-up. Previous IS (immunosuppressive drugs) include methotrexate, mycophenolate mofetil, azathioprine and cyclophosphamide, whereas biologics include anti-TNF alpha, tocilizumab and abatacept. Cut-off values to define DLCO and FVC were defined according to distribution.
ACA, anticentromeres; ANA, antinuclear antibodies; DLCO, diffusing capacity of lung for carbon monoxide; FVC, forced vital capacity; RNA pol III, RNA polymerases III antibodies.